Diabetes: Long-acting insulin analogues - Are benefits worth the cost?

Nature Reviews Endocrinology

Volumn 8, Issue 12, 2012, Pages 699-700

  Nathan, David M ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN ASPART; INSULIN DEGLUDEC; INSULIN DERIVATIVE; INSULIN DETEMIR;

CLINICAL TRIAL; DRUG COST; DRUG EFFECT; DRUG SAFETY; EVENING DOSAGE; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; LONG TERM CARE; PRIORITY JOURNAL; REVIEW; TREATMENT DURATION;

ADIPONECTIN; ALPHA-MSH; ANIMALS; ANTI-OBESITY AGENTS; CARDIOVASCULAR SYSTEM; DIET, HIGH-FAT; FEMALE; HUMANS; INSULIN RESISTANCE; IRON; MALE; OBESITY; PEPTIDES; RECEPTOR, MELANOCORTIN, TYPE 4; WEIGHT LOSS;

EID: 84870061237     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2012.208     Document Type: Review

References (10)

1. Hirsch, I. B. et al. Insulin degludec/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with type 1 diabetes: a 26-week phase 3, randomized, open-label, treat-to-target trial. Diabetes Care http://dx.doi.org/10.2337/dc11-2503.
2. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N. Engl. J. Med. 329, 977-986 (1993).
3. DCCT/EDIC Research Group et al. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N. Engl. J. Med. 365, 2366-2376 (2011).
4. Nathan, D. M. et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes mellitus. N. Engl. J. Med. 353, 2643-2653 (2005).
5. Birkeland, K. I. et al. Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine. Diabetes Care 34, 661-665 (2011).
6. Heller, S. et al. Insulin degludec, an ultra-long acting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 379, 1489-1497 (2012).
7. Le-Floch, J.-P. et al. Comparison of once-versus twice-daily administration of insulin detemir, used with mealtime insulin aspart, in basal-bolus therapy for type 1 diabetes. Diabetes Care 32, 32-37 (2009).
8. Deeb, L. C., Tan, M. H. & Alberti, K. G. Insulin availability among International Diabetes Federation member associations. Report of the Task Force on Insulin Distribution. Diabetes Care 17, 220-223 (1994).
9. Monami, M., Marchionni, N. & Mannucci, E. Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis. Diabetes Obes. Metab. 11, 372-378 (2009).
10. Sanches, A. C., Correr, C. J., Venson, R. & Pontarolo, R. Revisiting the efficacy of long-acting insulin analogues on adults with type 1 diabetes using mixed-treatment comparisons. Diabetes Res. Clin. Pract. 94, 333-339 (2011).